Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MGUS
MCID: MNC006
MIFTS: 53

Monoclonal Gammopathy of Uncertain Significance (MGUS)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Monoclonal Gammopathy of Uncertain Significance

About this section

MalaCards integrated aliases for Monoclonal Gammopathy of Uncertain Significance:

Name: Monoclonal Gammopathy of Uncertain Significance 12 15
Monoclonal Gammopathy of Undetermined Significance 12 76 53 73
Mgus 12 53

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:7442
ICD10 33 D47.2
UMLS 73 C0026470
Sources

Summaries for Monoclonal Gammopathy of Uncertain Significance

About this section
NIH Rare Diseases : 53 Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which an abnormal protein called monoclonal protein is detected in the blood. MGUS typically does not cause any problems, although some affected people may experience numbness, tingling or weakness. In some cases, MGUS may progress over time to certain forms of blood cancer (such as multiple myeloma, macroglobulinemia, or B-cell lymphoma). MGUS is thought to be a multifactorial condition that is likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. People with MGUS are usually monitored closely to ensure that the levels of monoclonal protein do not rise and other problems do not develop. Those with stable levels of monoclonal protein typically do not require treatment.

MalaCards based summary : Monoclonal Gammopathy of Uncertain Significance, also known as monoclonal gammopathy of undetermined significance, is related to peripheral nervous system disease and plasmacytoma. An important gene associated with Monoclonal Gammopathy of Uncertain Significance is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine Signaling in Immune system and NF-KappaB Family Pathway. The drugs Liraglutide and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related phenotypes are behavior/neurological and cellular

Wikipedia : 76 Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which a myeloma protein, an... more...

Sources

Related Diseases for Monoclonal Gammopathy of Uncertain Significance

About this section

Diseases related to Monoclonal Gammopathy of Uncertain Significance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 222)
# Related Disease Score Top Affiliating Genes
1 peripheral nervous system disease 30.7 IL6 MAG MYOM2 TNF
2 plasmacytoma 30.6 B2M CD38 IL6
3 human immunodeficiency virus infectious disease 30.4 B2M CD38 IL6 TNF
4 plasma cell leukemia 30.2 FGFR3 MAF NCAM1
5 poems syndrome 30.0 IL6 MYOM2 TNF
6 multiple sclerosis 29.8 IL6 LTA MAG TNF
7 lymphoma, non-hodgkin, familial 29.6 B2M CD19 CD38 MYOM2
8 leukemia, acute myeloid 29.6 CD19 CD38 NCAM1 TNF
9 bone disease 29.2 B2M DKK1 FGFR3 IL6 TNF
10 myeloma, multiple 28.6 B2M CD19 CD38 DKK1 FGFR3 IL6
11 light chain deposition disease 11.8
12 macroglobulinemia, waldenstrom 1 11.2
13 waldenstrom macroglobulinemia 11.1
14 helicobacter pylori infection 10.4
15 thrombosis 10.3
16 chronic neutrophilic leukemia 10.3
17 fanconi syndrome 10.3
18 scorpion envenomation 10.3 IL6 TNF
19 leukomalacia 10.3 IL6 TNF
20 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL6 TNF
21 critical limb ischemia 10.3 IL6 TNF
22 juvenile ankylosing spondylitis 10.3 IL6 TNF
23 cardiogenic shock 10.3 IL6 TNF
24 indolent myeloma 10.2 B2M MYOM2
25 miller fisher syndrome 10.2 MAG TNF
26 mononeuritis multiplex 10.2 MAG MYOM2
27 mononeuritis of upper limb and mononeuritis multiplex 10.2 MAG MYOM2
28 retinitis pigmentosa 55 10.2 IL6 TNF
29 polyclonal hypergammaglobulinemia 10.2 IL6 MYOM2
30 anca-associated vasculitis 10.2 IL6 TNF
31 chronic polyneuropathy 10.2 MAG MYOM2
32 acquired von willebrand syndrome 10.2
33 glossitis 10.2 IL6 TNF
34 laryngitis 10.2 IL6 TNF
35 null-cell leukemia 10.2 IL6 LTA TNF
36 autoimmune disease 10.2
37 leukemia, chronic lymphocytic 2 10.2
38 leukemia, chronic lymphocytic 10.2
39 thrombophilia due to thrombin defect 10.2
40 human herpesvirus 8 10.2
41 glomerulonephritis 10.2
42 neutropenia 10.2
43 lymphocytic leukemia 10.2
44 von willebrand's disease 10.2
45 dense deposit disease 10.2
46 idiopathic neutropenia 10.2
47 leukemia, b-cell, chronic 10.2
48 acute respiratory distress syndrome 10.2 IL6 LTA TNF
49 commensal bacterial infectious disease 10.2 IL6 MYOM2 TNF
50 rheumatic fever 10.2 IL6 MYOM2 TNF

Graphical network of the top 20 diseases related to Monoclonal Gammopathy of Uncertain Significance:



Diseases related to Monoclonal Gammopathy of Uncertain Significance
Sources

Symptoms & Phenotypes for Monoclonal Gammopathy of Uncertain Significance

About this section

MGI Mouse Phenotypes related to Monoclonal Gammopathy of Uncertain Significance:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.26 CD19 FGFR3 IL6 LTA MAF MAFB
2 cellular MP:0005384 10.24 B2M CD19 CD38 DKK1 FGFR3 IL6
3 homeostasis/metabolism MP:0005376 10.23 B2M CD19 CD38 DKK1 FGFR3 IL6
4 growth/size/body region MP:0005378 10.19 B2M CD19 DKK1 FGFR3 IL6 LTA
5 mortality/aging MP:0010768 10.18 B2M CD19 DKK1 FGFR3 IL6 LTA
6 immune system MP:0005387 10.17 B2M CD19 CD38 FGFR3 IL6 LTA
7 cardiovascular system MP:0005385 10.15 B2M CD19 IL6 LTA MAFB MYD88
8 hematopoietic system MP:0005397 10.13 B2M CD19 CD38 FGFR3 IL6 LTA
9 nervous system MP:0003631 10.1 B2M CD19 DKK1 FGFR3 IL6 LTA
10 digestive/alimentary MP:0005381 10.05 B2M CD19 FGFR3 IL6 MYD88 NSD2
11 craniofacial MP:0005382 10 DKK1 FGFR3 MAF MAFB NSD2 TNF
12 neoplasm MP:0002006 9.85 B2M CD19 FGFR3 IL6 MYD88 TNF
13 renal/urinary system MP:0005367 9.8 CD19 DKK1 FGFR3 IL6 MAF MAFB
14 respiratory system MP:0005388 9.7 DKK1 FGFR3 IL6 LTA MAFB MYD88
15 skeleton MP:0005390 9.56 DKK1 FGFR3 IL6 LTA MAFB MYD88
16 vision/eye MP:0005391 9.23 DKK1 FGFR3 IL6 LTA MAF MYD88
Sources

Drugs & Therapeutics for Monoclonal Gammopathy of Uncertain Significance

About this section

Drugs for Monoclonal Gammopathy of Uncertain Significance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 236)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Liraglutide Approved Phase 4 204656-20-2 44147092
2 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
3 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
4 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
5 Hormones Phase 4,Phase 3,Phase 2,Phase 1
6 Hormone Antagonists Phase 4,Phase 2,Phase 1
7 Hypoglycemic Agents Phase 4
8 glucagon Phase 4
9 Incretins Phase 4
10 Glucagon-Like Peptide 1 Phase 4
11
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
12
Iron Approved Phase 3 7439-89-6 23925
13
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
14
Ondansetron Approved Phase 3 99614-02-5 4595
15
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
16
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
17
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
20
Dalteparin Approved Phase 3 9005-49-6
21
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
22
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
23
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 22916-47-8 4189
24
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
25
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
26 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
27 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antirheumatic Agents Phase 3,Phase 2,Phase 1
29 Autonomic Agents Phase 3,Phase 2,Phase 1
30 Antiemetics Phase 3,Phase 2,Phase 1
31 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
32 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
35 Ferric Compounds Phase 3
36 Hematinics Phase 3,Phase 2
37 Iron Supplement Phase 3
38 ferric gluconate Phase 3
39 Central Nervous System Depressants Phase 3,Not Applicable
40 Antipsychotic Agents Phase 3
41 Dermatologic Agents Phase 3,Phase 1,Phase 2
42 Serotonin Antagonists Phase 3
43 Psychotropic Drugs Phase 3
44 Anti-Anxiety Agents Phase 3
45 Serotonin Agents Phase 3
46 Tranquilizing Agents Phase 3
47 Neurotransmitter Agents Phase 3,Phase 2
48 Antipruritics Phase 3
49 Respiratory System Agents Phase 3,Not Applicable
50 Analgesics Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 106)
# Name Status NCT ID Phase Drugs
1 Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat Not yet recruiting NCT02920190 Phase 4 Liraglutide
2 RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy Completed NCT00259974 Phase 3 Rituximab
3 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
4 Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device Completed NCT01210716 Phase 3
5 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
6 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
7 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
8 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
9 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
12 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
13 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
14 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
15 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
16 Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Unknown status NCT02566265 Phase 2
17 The Treatment of Lenalidomide in Patients With POEMS Syndrome Unknown status NCT00971685 Phase 2 Lenalidomide and dexamethasone
18 Beta Alethine in Treating Patients With Myeloma Unknown status NCT00006466 Phase 1, Phase 2 beta alethine
19 The Efficacy and Safety of ITF2357 in AIS Unknown status NCT00442182 Phase 2 ITF2357
20 Imaging in MGUS, SMM and MM Completed NCT01237054 Phase 2 18-NaF PET;18-FDG PET/CT
21 Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma Completed NCT00099047 Phase 2 celecoxib;placebo
22 Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma Completed NCT00006219 Phase 2 clarithromycin;prasterone
23 Ilaris (Canakinumab) in the Schnitzler Syndrome Completed NCT01245127 Phase 2 Ilaris
24 Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias Completed NCT02041325 Phase 2 Lenalidomide;Placebo
25 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
26 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
27 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
28 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
29 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
30 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
31 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
32 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
33 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
34 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
35 A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma Completed NCT01063907 Phase 1, Phase 2 KW-2478;Bortezomib
36 Ilaris® Effects in Schnitzler Syndrome (ILESCH) Completed NCT01390350 Phase 2 Canakinumab;Placebo
37 Efficacy and Safety of Canakinumab in Schnitzler Syndrome Completed NCT01276522 Phase 2 Canakinumab
38 Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) Completed NCT01045772 Phase 2 rilonacept
39 Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma Recruiting NCT03236428 Phase 2 Daratumumab
40 Daratumumab in Treatment of PGNMID and C3 GN Recruiting NCT03095118 Phase 2 Daratumumab
41 Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome Recruiting NCT02921893 Phase 2 Dexamethasone;Ixazomib Citrate;Lenalidomide
42 Tocilizumab in Patients With Schnitzler's Syndrome Recruiting NCT03046381 Phase 2 Tocilizumab
43 Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome Recruiting NCT03595371 Phase 2 dapansutrile
44 Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance Terminated NCT00665652 Phase 2 Lenalidomide
45 Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance Terminated NCT00588822 Phase 2
46 Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma Terminated NCT00942422 Phase 2
47 Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) Terminated NCT00899353 Phase 2
48 Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma Terminated NCT00538824 Phase 2 dexamethasone;thalidomide;lenalidomide
49 Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment Terminated NCT01548573 Phase 2 Dexamethasone;Cisplatin;Doxorubicin;Cyclophosphamide;Etoposide;Bortezomib;Thalidomide;Melphalan
50 Imaging Studies and the Development of Multiple Myeloma Withdrawn NCT01571726 Phase 2 Fluciclatide

Search NIH Clinical Center for Monoclonal Gammopathy of Uncertain Significance

Sources

Genetic Tests for Monoclonal Gammopathy of Uncertain Significance

About this section
Sources

Anatomical Context for Monoclonal Gammopathy of Uncertain Significance

About this section

MalaCards organs/tissues related to Monoclonal Gammopathy of Uncertain Significance:

41
Bone, Bone Marrow, B Cells, Testes, T Cells, Myeloid, Kidney
Sources

Publications for Monoclonal Gammopathy of Uncertain Significance

About this section

Articles related to Monoclonal Gammopathy of Uncertain Significance:

(show top 50) (show all 548)
# Title Authors Year
1
Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). ( 29424556 )
2018
2
Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance (SLONM-MGUS): An alternative treatment using cyclophosphamide-thalidomide-dexamethasone (CTD) regimen. ( 29910095 )
2018
3
Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. ( 28479151 )
2018
4
Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. ( 28540748 )
2018
5
Treatment with bortezomib in dense deposit disease associated with monoclonal gammopathy of undetermined significance. ( 29363742 )
2018
6
Combination of acquired von Willebrand syndrome (AVWS) and Glanzmann thrombasthenia in monoclonal gammopathy of uncertain significance (MGUS), a case report. ( 30534006 )
2018
7
Increased activated regulatory T cell subsets and aging Treg-like cells in multiple myeloma and monoclonal gammopathy of undetermined significance: a case control study. ( 30479566 )
2018
8
Mixed cryoglobulinemic membranoproliferative glomerulonephritis due to monoclonal gammopathy of undetermined significance: A case report. ( 30213019 )
2018
9
Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case report. ( 30383696 )
2018
10
Meningitis, spondylodiscitis, pneumonia and septic shock with Streptococcus pneumoniae in a previously healthy woman with isolated IgG2-, IgG3-, IgA-deficiency and monoclonal gammopathy of undetermined significance. ( 29721239 )
2018
11
Leukocytoclastic vasculitis associated with immunoglobulin A lambda monoclonal gammopathy of undetermined significance: A case report and review of previously reported cases. ( 29766549 )
2018
12
Sarcoidosis and Monoclonal Gammopathy of Undetermined Significance (MGUS): A True Association or Just a Coincidence? ( 30356364 )
2018
13
MALDI-TOF analysis of blood serum proteome can predict the presence of monoclonal gammopathy of undetermined significance. ( 30071092 )
2018
14
Multiparameter Flow Cytometry Identification of Neoplastic Subclones: A New Biomarker in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. ( 30428459 )
2018
15
Prostate cancer leading to monoclonal gammopathy of undetermined significance: A case report. ( 30155257 )
2018
16
The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and monoclonal gammopathy of renal significance. ( 30169860 )
2018
17
Case Report: Monoclonal Gammopathy of Undetermined Significance is Associated with Loa loa Infection. ( 30203743 )
2018
18
Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis. ( 30229522 )
2018
19
What is the significance of monoclonal gammopathy of undetermined significance? ( 30287433 )
2018
20
A case of monoclonal gammopathy of undetermined significance with abnormal low levels of plasma glycated albumin by M protein. ( 30317021 )
2018
21
Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance: a retrospective study. ( 30406907 )
2018
22
Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma. ( 30453544 )
2018
23
Disrupted radial and tibial microarchitecture in patients with monoclonal gammopathy of undetermined significance. ( 30488275 )
2018
24
Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS). ( 30541309 )
2018
25
Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis. ( 28243796 )
2018
26
Monoclonal gammopathy of undetermined significance as viewed by haematology healthcare professionals. ( 28885714 )
2018
27
Hemorheological parameters in Monoclonal Gammopathy of Undetermined Significance (MGUS). ( 29036799 )
2018
28
How I manage monoclonal gammopathy of undetermined significance. ( 29183887 )
2018
29
Risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies: determining demographic differences in the USA. ( 29269527 )
2018
30
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. ( 29342381 )
2018
31
Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. ( 29568092 )
2018
32
Light chain monoclonal gammopathy of undetermined significance is characterized by a high disappearance rate and low risk of progression on longitudinal analysis. ( 29629484 )
2018
33
Normolipemic eruptive xanthoma in a patient with monoclonal gammopathy of undetermined significance. ( 29731133 )
2018
34
Lichen myxedematosus associated with monoclonal gammopathy of undetermined significance: A case report and a review of Japanese patients. ( 29963716 )
2018
35
Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance. ( 29977018 )
2018
36
Prevalence of Monoclonal Gammopathy of Undetermined Significance in India-A Hospital-based Study. ( 29980412 )
2018
37
Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study. ( 30117173 )
2018
38
Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction study. ( 30134812 )
2018
39
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. ( 28550183 )
2017
40
Pattern of somatic mutations in patients with WaldenstrAPm macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. ( 28983055 )
2017
41
Management of Patients With Hepatitis C Virus, Monoclonal Gammopathy of Undetermined Significance, and Multiple Myeloma. ( 28748190 )
2017
42
Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance. ( 28943951 )
2017
43
Paraproteinemic keratopathy in monoclonal gammopathy of undetermined significance treated with primary keratoprosthesis: Case report, histopathologic findings, and world literature review. ( 29390260 )
2017
44
Diffuse Peritoneal and Bowel Wall Infiltration by Light Chain-AL Amyloidosis with Omental Calcification Mimicking Abdominal Carcinomatosis - An Elderly Female with Incidental Finding of Light Chain Monoclonal Gammopathy of Undetermined Significance (LC-MGUS). ( 29176541 )
2017
45
Bilateral striopallidodentate calcinosis associated with SjAPgren's syndrome and IgDI> monoclonal gammopathy of undetermined significance. ( 29183861 )
2017
46
Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance. ( 28678037 )
2017
47
Pure Red Cell Aplasia Associated with Monoclonal Gammopathy of Undetermined Significance and Literature Review. ( 28182355 )
2017
48
Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering WaldenstrAPm macroglobulinaemia. ( 27605200 )
2017
49
History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. ( 27807648 )
2017
50
Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study. ( 29296931 )
2017
Sources

Variations for Monoclonal Gammopathy of Uncertain Significance

About this section

Copy number variations for Monoclonal Gammopathy of Uncertain Significance from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13350 1 1 125000000 Gain Monoclonal gammopathy of undetermined significance
2 16482 1 125000000 249250621 Gain Monoclonal gammopathy of undetermined significance
3 55476 11 53700000 135006516 Gain Monoclonal gammopathy of undetermined significance
4 76533 13 32200000 40100000 Deletion NBEA Monoclonal gammopathy of undetermined significance
5 82835 14 17600000 107349540 Loss Monoclonal gammopathy of undetermined significance
6 89754 15 19000000 102531392 Gain Monoclonal gammopathy of undetermined significance
7 124088 19 1 26500000 Gain Monoclonal gammopathy of undetermined significance
8 166137 3 1 91000000 Gain Monoclonal gammopathy of undetermined significance
9 214491 6 61000000 171115067 Loss Monoclonal gammopathy of undetermined significance
10 253951 9 49000000 141213431 Gain Monoclonal gammopathy of undetermined significance
Sources

Expression for Monoclonal Gammopathy of Uncertain Significance

About this section
Search GEO for disease gene expression data for Monoclonal Gammopathy of Uncertain Significance.
Sources

Pathways for Monoclonal Gammopathy of Uncertain Significance

About this section

Pathways related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 66
Show member pathways
 13.11 B2M FGFR3 IL6 LTA MYD88 NCAM1
2
NF-KappaB Family Pathway 64
Show member pathways
 12.42 FGFR3 IL6 LTA MYD88 TNF
3
NF-kappaB Signaling 4
12.15 B2M CD19 CD38 MYD88 NCAM1 TNF
4
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.07 FGFR3 IL6 LTA TNF
5
Epstein-Barr virus infection 37
11.96 B2M CD19 IL6 MYD88 TNF
6
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.89 DKK1 IL6 NCAM1
7
Th1 Differentiation Pathway 65
Show member pathways
 11.87 IL6 LTA TNF
8
Spinal Cord Injury 1
11.82 IL6 MAG TNF
9
TNF signaling pathway 37
11.77 IL6 LTA TNF
10
NF-kappa B signaling pathway 37
11.69 LTA MYD88 TNF
11
Hematopoietic cell lineage 37
11.61 CD19 CD38 IL6 TNF
12
Innate Lymphoid Cell Differentiation Pathways 65
11.6 LTA NCAM1 TNF
13
Pertussis 37
11.57 IL6 MYD88 TNF
14
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.42 CD19 CD38 IL6 NCAM1 TNF
15
Legionellosis 37
11.41 IL6 MYD88 TNF
16
Transcription_NF-kB signaling pathway 22
11.39 LTA MYD88 TNF
17
Malaria 37
11.3 IL6 MYD88 TNF
18
African trypanosomiasis 37
11.09 IL6 MYD88 TNF
19
Transcription factor regulation in adipogenesis 1
10.94 IL6 TNF
20
Dendritic Cells Developmental Lineage Pathway 65
10.89 CD19 CD38 IL6 NCAM1 TNF
21
Overview of nanoparticle effects 1
10.86 IL6 TNF
Sources

GO Terms for Monoclonal Gammopathy of Uncertain Significance

About this section

Cellular components related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.26 B2M CD19 NCAM1 TNF
2 cell surface GO:0009986 9.02 B2M CD38 FGFR3 NCAM1 TNF

Biological processes related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.95 CD38 DKK1 FGFR3 IL6 MYD88
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.75 IL6 MYD88 TNF
3 positive regulation of gene expression GO:0010628 9.72 DKK1 IL6 MAF MYD88 TNF
4 negative regulation of neuron projection development GO:0010977 9.67 B2M CD38 MAG
5 positive regulation of interleukin-6 production GO:0032755 9.63 IL6 MYD88 TNF
6 humoral immune response GO:0006959 9.61 IL6 LTA TNF
7 positive regulation of smooth muscle cell proliferation GO:0048661 9.58 IL6 MYD88 TNF
8 positive regulation of chemokine production GO:0032722 9.57 IL6 TNF
9 negative regulation of bone resorption GO:0045779 9.56 CD38 IL6
10 negative regulation of lipid storage GO:0010888 9.54 IL6 TNF
11 positive regulation of chemokine biosynthetic process GO:0045080 9.52 MYD88 TNF
12 response to peptidoglycan GO:0032494 9.51 IL6 MYD88
13 positive regulation of neuroinflammatory response GO:0150078 9.48 IL6 TNF
14 defense response to Gram-positive bacterium GO:0050830 9.46 IL6 LTA MYD88 TNF
15 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.37 LTA TNF
16 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.26 LTA TNF
17 positive regulation of glial cell proliferation GO:0060252 9.13 IL6 LTA TNF
18 negative regulation of growth of symbiont in host GO:0044130 8.8 LTA MYD88 TNF
Sources

Sources for Monoclonal Gammopathy of Uncertain Significance

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....